Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing ...

Pfizer PFE will report its third-quarter 2025 earnings on Nov. 4, before market open. The Zacks Consensus Estimate for sales ...

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered ...

Investors in Pfizer Inc (Symbol: PFE) saw new options begin trading today, for the September 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PFE options ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $26.5 for Pfizer over the last 3 months.

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment ...

One of the most appealing features of Pfizer's stock is its dividend. The payout recently yielded a hefty 7.4% -- and it's been growing over time. There's reason to be bullish over Pfizer's long-term ...